人民财讯11月24日电，上海市人民政府办公厅印发《上海市全面深化药品医疗器械监管改革促进医药产 业高质量发展的若干措施》，其中提出，推进医药产业数智化转型。推动人工智能技术与医药全产业链 融合，加快人工智能药物发现与设计系统应用，推动医药大模型赋能研发。鼓励生产企业数智化转型， 应用智能制药、实验室管理、制造执行等智能化系统，加快建设数智化、规模化、品牌化企业。鼓励我 市疫苗生产企业建设和改造生产线，严格落实生产检验过程信息化，血液制品企业建立覆盖采浆、入 厂、生产、检验全过程的信息化体系，实现全程追溯。鼓励医药流通企业构建供应链数智化协同平台， 推广智能仓储调度，促进供应链间数据电子化和应用共享。 ...

Core Viewpoint - The implementation of the "Pharmaceutical Industry Digital Transformation Implementation Plan (2025-2030)" by seven government departments aims to enhance the digital transformation across the entire pharmaceutical industry chain, focusing on the deep application of artificial intelligence technology and the cultivation of excellent enterprises [1][3]. Group 1: Market Impact - Following the announcement, the pharmaceutical digitalization sector in the A-share market saw a collective rise, with notable increases such as 13.16% for Sichuang Medical [2][1]. - The digital transformation plan is expected to create significant opportunities for the pharmaceutical industry, effectively equipping it with a "digital brain" to enhance efficiency and reduce costs [6][7]. Group 2: Development Goals - The plan outlines two key stages: by 2027, significant progress in digital transformation should be achieved, and by 2030, large-scale pharmaceutical enterprises should have fully realized digital transformation [3][4]. - Specific targets include the development of over 30 digital technology standards and the establishment of more than 100 exemplary application scenarios in the pharmaceutical industry [4][5]. Group 3: Key Tasks - The plan identifies four major tasks: empowering with digital technology, promoting digital transformation, building a digital service system, and enhancing digital regulation [5][6]. Group 4: Market Growth Potential - The digital healthcare market in China is projected to exceed 1.2 trillion yuan by the end of 2024, with a compound annual growth rate of 24.5% [8]. - By 2025, the digital healthcare market is expected to surpass 1.8 trillion yuan, and by 2030, it could reach 2.5 trillion yuan, indicating a significant market opportunity driven by policy, technology, and demand [9]. Group 5: Company Innovations - Companies like Hengrui Medicine and Fosun Pharma are collaborating with AI platforms to enhance the efficiency of innovative drug development [11]. - Other firms, such as WuXi AppTec and Chengdu XianDao, are integrating AI into their research processes to improve precision and efficiency in drug development [10][11].